Sign in
AQST Stock Price, Chart, Stats & News
Aquestive Therapeutics, Inc.
Save
Aquestive Therapeutics, Inc. (AQST) does not currently pay a dividend.
413.12M
Market cap
–
Current P/E
–
Forward P/E
AQST chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 58.35% |
Operating margin | -159.50% |
Pretax margin | -188.09% |
Net margin | -188.09% |
Effective tax rate | – |
ROA | -52.23% |
ROE | 195.65% |
D/E | -3.90x |
Interest coverage ratio | -4.16x |
AQST valuation
P/E | – |
P/S | 8.96x |
P/B | -14.57x |
P/CF | -9.35x |
P/FCF | -7.53x |
P/OCF | -9.35x |
PEG | 0.59x |
EV multiple | -6.02x |
About
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence.
Similar securities
Based on sector and market capitalization
Report issue